Cibc World Markets Corp Buys Shares of 4,169 PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Cibc World Markets Corp acquired a new stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,169 shares of the company's stock, valued at approximately $336,000.

A number of other institutional investors also recently bought and sold shares of PRCT. Raleigh Capital Management Inc. purchased a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at about $32,000. IFP Advisors Inc bought a new position in PROCEPT BioRobotics in the fourth quarter worth approximately $58,000. Arcadia Investment Management Corp MI bought a new position in PROCEPT BioRobotics in the fourth quarter worth approximately $64,000. Wilmington Savings Fund Society FSB purchased a new position in shares of PROCEPT BioRobotics during the 3rd quarter worth $64,000. Finally, Canton Hathaway LLC purchased a new stake in shares of PROCEPT BioRobotics in the 3rd quarter worth $66,000. Institutional investors own 89.46% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PRCT shares. Morgan Stanley lowered their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Wells Fargo & Company reaffirmed an "overweight" rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Finally, Truist Financial reissued a "buy" rating and issued a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $94.29.

Remove Ads

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Reza Zadno sold 5,475 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at $9,875,374.20. This represents a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kevin Waters sold 733 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,455 shares of company stock worth $368,322. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Price Performance

Shares of PRCT stock traded up $1.63 during mid-day trading on Tuesday, hitting $62.53. The company had a trading volume of 1,361,854 shares, compared to its average volume of 727,428. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The company has a market capitalization of $3.43 billion, a P/E ratio of -32.07 and a beta of 1.05. The stock's 50 day moving average price is $66.71 and its 200-day moving average price is $78.25. PROCEPT BioRobotics Co. has a 52-week low of $45.56 and a 52-week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).